Juliano Machado

Juliano Machado

Auto-generated profile, based on publicly available information

Juliano Machado

German Research Center for Environmental Health 1 Institute for Diabetes and Cancer (IDC), Helmholtz Munich Neuherberg, Germany

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2026 in Cancer Discovery
Verified
Journal Article
Open access
JMJuliano Machado
Juliano Machado
VKVignesh Karthikaisamy
Vignesh Karthikaisamy
HMHermine Mohr
Hermine Mohr
DKDoris Kaltenecker
Doris Kaltenecker
PBPia Benedikt
Pia Benedikt
MDMauricio Berriel Diaz
Mauricio Berriel Diaz
Cancer cachexia is a devastating wasting syndrome with no approved therapies. In this study, we identify the tumor-derived glycoprotein ADAMTSL4 as a circulating factor associated with body weight loss in preclinical cachexia models and patients with colorectal and lung cancers. In mice, Adamtsl4 overexpression converted non–cachexia-inducing tumors into cachexia-inducing tumors, whereas its deletion in cachexia-inducing tumors spared fat and muscle, blunted muscle atrophy signatures, and reduced cachexia severity. ADAMTSL4 engages the latency-associated peptide (LAP) of TGFβ1, promoting local activation of TGFβ1 at muscle cell membranes. Genetic blockade of proTGFβ1 or pharmacologic inhibition of TGFβ signaling reduced ADAMTSL4-dependent wasting in adipocytes and muscle cells. Suppression of tumor-derived ADAMTSL4 attenuated skeletal muscle fibrosis in mice. Together, the association between increased circulating ADAMTSL4 levels and TGFβ–driven muscle atrophy and fibrosis gene signatures in patients with cachectic cancer identifies ADAMTSL4 as an upstream regulator of TGFβ1 and a potential therapeutic target in cancer cachexia. Significance: Cancer cachexia lacks effective therapies and remains a major cause of cancer-related morbidity and mortality. We identify tumor-derived ADAMTSL4 as an upstream regulator of latent TGFβ activation via LAP engagement that promotes multiorgan wasting and fibrosis-related remodeling. Targeting ADAMTSL4 may provide a selective therapeutic strategy without systemic TGFβ pathway blockade. See related commentary by Liu and Janowitz, p. 1964

1 October 2026
Verified
Other
Open access
JMJuliano Machado
Juliano Machado
VKVignesh Karthikaisamy
Vignesh Karthikaisamy
HMHermine Mohr
Hermine Mohr
DKDoris Kaltenecker
Doris Kaltenecker
PBPia Benedikt
Pia Benedikt
MDMauricio Berriel Diaz
Mauricio Berriel Diaz
ADAMTSL4 induces skeletal muscle fibrosis via local TGFβ signaling and activates fibrosis-related genes in human myotubes and muscles of patients with cancer cachexia. A and B, GSEA (A) of GC muscle from MC38-GFP vs. MC38-ADAMTSL4 tumor-bearing mice showing enrichment of the “TGFβ receptor signaling” pathway and heatmap (B) of the top 10 DEGs within this pathway. C and D, GSEA (C) of GC muscle from C26-shCtrl vs. C26-shAdamtsl4 tumor-bearing mice showing enrichment of “TGFβ receptor signaling activates SMADs” and heatmap (D) of the top 10 DEGs. E, Representative Sirius Red (top) and collagen-I (bottom) staining in GC muscle sections from PBS-injected, C26-shCtrl, and C26-shAdamtsl4 tumor-bearing mice (scale bar, 100 μm). F–K, Human primary myotubes were treated with rhADAMTSL4-CT (250 ng/mL) in the presence or absence of TGFβ pathway blockade: (F) mRNA levels of fibrosis-related genes (TGFB1, CTGF, and TGFBI); (G) atrophy-related genes (FBXO32 and TRIM63) measured by qPCR; (H) quantification of myotube diameter; (I) representative images of myotubes treated with vehicle or rhADAMTSL4-CT ± TGFβ1–neutralizing antibody 1D11 (1.5 μg/mL; scale bar, 100 μm); (J) Western blot analysis of phosphorylated SMAD2 (p-SMAD2); (K) qPCR analysis of CTGF and TGM2 mRNA levels in myotubes treated with vehicle or rhADAMTSL4-CT ± galunisertib (10 μmol/L), a TGFBR1 inhibitor. L and M, Relative body weight change and circulating ADAMTSL4 levels measured by ELISA in an exploratory human cancer subcohort including patients with colorectal cancer and PDAC classified as cachectic (cancer cachexia, n = 15) or noncachectic (non–cancer cachexia, n = 7). N–P, qPCR analysis of TGFB1, TGM2, and FBXO21 mRNA expression in rectus abdominis muscle biopsies from non–cancer cachexia patients and those with cancer cachexia with colorectal cancer/PDAC. Q, Schematic model depicting how tumor-derived ADAMTSL4 promotes muscle wasting via local activation of TGFβ signaling through LAP engagement and TGFBR1-dependent transcriptional responses. Data are shown as the mean ± SEM unless indicated otherwise. Each dot represents one biological replicate. Statistical analysis: weighted Kolmogorov–Smirnov test for GSEA enrichment scores (A and C); two-way mixed-effects model with Tukey or Holm–Šídák multiple-comparisons test (F–H, J, and K); for circulating ADAMTSL4 measurements in human plasma (M), ELISA values were log10-transformed and analyzed using a two-tailed Mann–Whitney test; human gene expression comparisons (N–P) were analyzed using two-tailed Mann–Whitney tests. Significance is denoted as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. [Q, Created in BioRender. Machado, J. (2026) https://BioRender.com/4sidioq.]

1 October 2026
Verified
Other
Open access
PDF file
JMJuliano Machado
Juliano Machado
VKVignesh Karthikaisamy
Vignesh Karthikaisamy
HMHermine Mohr
Hermine Mohr
DKDoris Kaltenecker
Doris Kaltenecker
PBPia Benedikt
Pia Benedikt
MDMauricio Berriel Diaz
Mauricio Berriel Diaz
Supplementary Fig. S1. ADAMTSL4 is enriched in conditioned media of cachexia-inducing cancer cell lines and is associated with systemic metabolic alterations in patients with cancer. Supplementary Fig. S2. Overexpression of ADAMTSL4 converts non-cachexia-inducing cells into cachexia-inducing cells. Supplementary Fig. S3. Stable knockdown of ADAMTSL4 in cachexia-inducing cells attenuates their muscle-wasting capacity in vitro. Supplementary Fig. S4. Stable knockdown of ADAMTSL4 in cachexia-inducing tumor cells attenuates in vitro and in vivo adipocyte wasting and prolongs cachexia-related survival. Supplementary Fig. S5. ADAMTSL4 targets LAP of latent TGF-β1 complex to promote myotube atrophy via TGF-β latency activation and TGFβR-dependent signaling. Supplementary Fig. S6. ADAMTSL4 induces wasting of murine and human white adipocytes via local activation of TGF-β1–TGFBR1 signaling, without altering circulating TGF-β1 levels.

1 October 2026
Verified
Other
Open access
JMJuliano Machado
Juliano Machado
VKVignesh Karthikaisamy
Vignesh Karthikaisamy
HMHermine Mohr
Hermine Mohr
DKDoris Kaltenecker
Doris Kaltenecker
PBPia Benedikt
Pia Benedikt
MDMauricio Berriel Diaz
Mauricio Berriel Diaz
Stable knockdown of tumor-derived ADAMTSL4 attenuates adipose tissue wasting, prolongs cachexia-related survival, and protects against cancer-induced cardiac atrophy. A–R, Mice were subcutaneously injected with PBS, control C26 cells (C26-shCtrl), or ADAMTSL4-depleted C26 cells (C26-shAdamtsl4). A, Schematic overview of the preclinical model used to assess the impact of tumor-derived ADAMTSL4 on adipose wasting, survival, and cardiac atrophy. B, Relative fat mass changes measured by EchoMRI. C, Mass of individual fat depots: iWAT, eWAT, and BAT. D, Plasma glycerol levels normalized to final fat mass. E, Selected GO terms from GSEA of eWAT comparing C26-shAdamtsl4 vs. C26-shCtrl tumor-bearing mice (see also Supplementary Data S7 and S8 for full GO term analysis results). F, mRNA expression of lipolysis-related genes and (G) fatty acid oxidation genes in eWAT, validating GSEA-enriched “fatty acid oxidation” and “lipid oxidation” terms. H, Western blot analysis of ATGL protein levels. I, Western blot analysis of autophagy-related proteins in eWAT, supporting the “autophagy” GO term from GSEA. J–R, Mice were subcutaneously inoculated with PBS (n = 5), C26-shCtrl cells (n = 6–7), or C26-shAdamtsl4 cells (n = 6–9). J, Tumor mRNA expression of Adamtsl4, Mki67, Bbc3, and Pmaip1 assessed by qPCR. K, Plasma ADAMTSL4 protein levels measured by Western blot. L, Kaplan–Meier curve showing percentage of mice developing cachexia over time. M, Percentage of cachexia-free mice at endpoint. N, Representative heart sections stained with WGA Alexa Fluor 488 and DAPI (200× magnification; scale bar, 100 μm). Representative structural features are highlighted by arrows (white, PBS/control; red, cachectic condition; blue, ADAMTSL4 knockdown). O, CSA quantification of cardiomyocytes (n = 3 per group, >200 cells per mouse). P, Cardiac expression of autophagy-related genes (Bnip3, Map1lc3, and Gabarapl1) by qPCR. Q, Western blot analysis of cardiac autophagy (LC3-I and LC3-II) and (R) apoptosis (BAX) markers. Data are presented as the mean ± SEM. Each dot represents an individual biological replicate. Statistical analysis: one-way ANOVA with Tukey multiple-comparisons test (B–D, F–I, K, and O), multiple two-tailed unpaired t tests with Welch correction (J), two-way ANOVA or mixed-effects model (REML) with Tukey multiple-comparisons test (P–R), and GSEA enrichment scores calculated using weighted Kolmogorov–Smirnov statistics (E). Significance is denoted as *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant. [A, Created in BioRender. Machado, J. (2026) https://BioRender.com/79ygt3l.]

1 October 2026
Verified
Other
Open access
JMJuliano Machado
Juliano Machado
VKVignesh Karthikaisamy
Vignesh Karthikaisamy
HMHermine Mohr
Hermine Mohr
DKDoris Kaltenecker
Doris Kaltenecker
PBPia Benedikt
Pia Benedikt
MDMauricio Berriel Diaz
Mauricio Berriel Diaz
Circulating ADAMTSL4 levels are elevated in cancer cachexia. A and B, Relative body weight (BW) change (% of initial BW; A) and plasma ADAMTSL4 protein levels measured by ELISA (B) in cachectic C26 tumor-bearing mice (n = 8), noncachectic MC38 tumor-bearing mice (n = 10), and PBS-injected controls (n = 13). C and D, Relative BW change (C) and plasma ADAMTSL4 levels (D) in cachectic ApcMin/+ mice (n = 6) vs. wild-type (WT) littermates (n = 6). E and F, Relative BW change (E) and plasma ADAMTSL4 levels (F) in cachectic LLC tumor-bearing mice (n = 16) and PBS-injected controls (n = 11). G, Spearman correlation between plasma ADAMTSL4 levels and relative BW change across all mouse models (n = 70 XY pairs; pooled from A–F). H and I, Relative BW change (H) and circulating ADAMTSL4 levels (I; ELISA, log10 scale) in noncachectic (non–cancer cachexia, n = 20) and cachectic (cancer cachexia, n = 27) patients with colorectal cancer. J and K, Spearman correlations in patients with colorectal cancer between circulating ADAMTSL4 levels and relative BW change (J; n = 47 XY pairs) or cachexia grade (K; n = 47 XY pairs). L, ROC analysis comparing circulating ADAMTSL4 with established cachexia-associated biomarkers in patients with colorectal cancer. M and N, Relative BW change (M) and circulating ADAMTSL4 protein levels (N) in noncachectic (n = 30) and cachectic (n = 14) patients with LUAD from the TRACERx cohort. ADAMTSL4 was quantified by Olink proximity extension assay and is reported as NPX (log2-scaled relative abundance units). O and P, Spearman correlations between ADAMTSL4 NPX values and relative BW change (O; n = 44 XY pairs) or cachexia grade (P; n = 44 XY pairs) in patients with LUAD. Q, Kaplan–Meier analysis of OS in patients with NSCLC from the TRACERx cohort stratified by high vs. low circulating ADAMTSL4 (median NPX as cutoff). R, Kaplan–Meier analysis of disease-free survival in patients with NSCLC from the TRACERx cohort stratified by high vs. low circulating ADAMTSL4 (median NPX as cutoff). Data are presented as the mean ± SEM for mouse experiments (A–F). Relative BW change in patient cohorts (H and M) is shown with individual data points and mean ± SEM. For human biomarker group comparisons (I and N), data are shown as box-and-whisker plots with individual data points overlaid. Boxes indicate the interquartile range, center lines indicate the median, and whiskers indicate Tukey whiskers (1.5 × IQR). ELISA-based ADAMTSL4 concentrations in patients with colorectal cancer (I) are shown on a log10-transformed scale, whereas circulating ADAMTSL4 levels in patients with LUAD (N) are presented as NPX values (log2 scale). Due to differences in measurement platforms, values were analyzed within each cohort and were not directly compared across datasets. Statistical analysis: one-way ANOVA with Tukey multiple-comparisons test (A and B), two-tailed unpaired t test (C–F), and Spearman correlation (G). Human data were systematically evaluated for normality and outliers (ROUT, Q = 1%). For ELISA-based comparisons in colorectal cancer (I), distributions were right-skewed; therefore, two-tailed Mann–Whitney tests were used as the primary analysis, with Welch t test on log10-transformed data performed as sensitivity analysis (see “Methods”). Group comparisons in patients (H, I, M, and N) were analyzed using two-tailed Mann–Whitney tests. Correlation analyses in human cohorts (J, K, O, and P) were performed using two-tailed Spearman rank correlation. ROC analysis (L) was used to compare biomarker performance for discrimination of cachectic vs. noncachectic patients with colorectal cancer. Kaplan–Meier survival curves (Q and R) were compared using the log-rank (Mantel–Cox) test. Significance is denoted as *, P < 0.05; ***, P < 0.001; ****, P < 0.0001; ns, not significant.

1 October 2026
Verified
Other
Open access
PDF file
JMJuliano Machado
Juliano Machado
VKVignesh Karthikaisamy
Vignesh Karthikaisamy
HMHermine Mohr
Hermine Mohr
DKDoris Kaltenecker
Doris Kaltenecker
PBPia Benedikt
Pia Benedikt
MDMauricio Berriel Diaz
Mauricio Berriel Diaz
Table S1: Characterization of colorectal cancer patients. Table S2: Characterization of Lung cancer adenocarcinoma stratified from NSCLC cohort, cancer cachexia cohort 3 (29). Table S3: Enrichment of proteins obtained in Ligand-receptor capture followed LC-MS/MS analysis. Table S4: RRID Addendum.